|Awarded On||August 16, 2023|
|Title||Unraveling the Therapeutic Potential of Osr1 Overexpression in Hepatocellular Carcinoma Management|
|Award Mechanism||TREC: Pilot Study Award|
|Institution/Organization||Texas A&M University|
|Principal Investigator/Program Director||Linglin Xie|
|Cancer Sites||Gallbladder, Liver and Intrahepatic Bile Duct|
*Pending contract negotiation
Liver cancer, particularly hepatocellular carcinoma (HCC), is a rapidly growing cancer in the US, with a poor prognosis and limited treatment options. Texas has a higher incidence rate of liver cancer compared to the national average, likely due to the high prevalence of risk factors such as viral infections, excessive alcohol consumption, and fatty liver, as well as a large population of Hispanics and African Americans who are at higher risk. In addition, rural areas of Texas face challenges with delayed diagnosis and treatment due to a shortage of healthcare professionals and facilities. Conventional treatments for liver cancer often have low efficacy and severe side effects, necessitating...